APS Booth Presentation: Patterns of Opioid Metabolites in Urine - the Buprenorphine story
Blood is an ideal specimen for evaluating adherence to therapy in patients who cannot provide urine, to support pharmacokinetic studies, and to reduce the opportunity for specimen adulteration. However, testing for drugs in blood with traditional immunoassay-based technologies is associated with many limitations in sensitivity and specificity. This presentation will describe the improvements in sensitivity and specificity gained by a novel mass spectrometric approach to drug screening with blood.
Originally presented May 17, 2012 in Honolulu, Hawaii.
Gwendolyn A. McMillin, PhD
Medical Director, Toxicology and Trace Elements Laboratories, ARUP Laboratories
Co-Medical Director, Pharmacogenetics, ARUP Laboratories
Associate Professor of Pathology, University of Utah School of Medicine
Dr. McMillin is a medical director of the Toxicology and Trace Elements laboratories and co-medical director of Pharmacogenetics at ARUP, as well as an associate professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.